Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the alpha-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 +/- 5.9 years, the mean disease duration was 13 +/- 6.3 years, and mean Hoehn and Yahr stage was 2.2 +/- 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.
Singer
Carlos
C
Department of Neurology University of Miami, School of Medicine, Miami, Florida 33136, USA. csinger@med.miami.edu
Papapetropoulos
Spiridon
S
Gonzalez
Manuel A
MA
Roberts
Eugene L
EL
Lieberman
Abraham
A
D000368:Aged; D000547:Amantadine / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D012299:Rimantadine / Q000627:therapeutic use*; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D012299:Rimantadine; D000547:Amantadine